223 related articles for article (PubMed ID: 23602926)
1. Connectivity maps for biosimilar drug discovery in venoms: the case of Gila monster venom and the anti-diabetes drug Byetta®.
Aramadhaka LR; Prorock A; Dragulev B; Bao Y; Fox JW
Toxicon; 2013 Jul; 69():160-7. PubMed ID: 23602926
[TBL] [Abstract][Full Text] [Related]
2. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent.
Furman BL
Toxicon; 2012 Mar; 59(4):464-71. PubMed ID: 21194543
[TBL] [Abstract][Full Text] [Related]
3. Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from the saliva of the Gila monster.
Alves PL; Abdalla FMF; Alponti RF; Silveira PF
Toxicon; 2017 Sep; 135():1-11. PubMed ID: 28579479
[TBL] [Abstract][Full Text] [Related]
4. Exenatide: from the Gila monster to the pharmacy.
Triplitt C; Chiquette E
J Am Pharm Assoc (2003); 2006; 46(1):44-52; quiz 53-5. PubMed ID: 16529340
[TBL] [Abstract][Full Text] [Related]
5. Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues.
Pohl M; Wank SA
J Biol Chem; 1998 Apr; 273(16):9778-84. PubMed ID: 9545315
[TBL] [Abstract][Full Text] [Related]
6. Isolation and cloning of exendin precursor cDNAs from single samples of venom from the Mexican beaded lizard (Heloderma horridum) and the Gila monster (Heloderma suspectum).
Chen T; Kwok H; Ivanyi C; Shaw C
Toxicon; 2006 Mar; 47(3):288-95. PubMed ID: 16386282
[TBL] [Abstract][Full Text] [Related]
7. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the gila monster (Heloderma suspectum suspectum) venom proteome.
Sanggaard KW; Dyrlund TF; Thomsen LR; Nielsen TA; Brøndum L; Wang T; Thøgersen IB; Enghild JJ
J Proteomics; 2015 Mar; 117():1-11. PubMed ID: 25603280
[TBL] [Abstract][Full Text] [Related]
9. Exenatide. Amylin/Eli Lilly.
Giannoukakis N
Curr Opin Investig Drugs; 2003 Apr; 4(4):459-65. PubMed ID: 12808888
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
11. Black widow spider alpha-latrotoxin: a presynaptic neurotoxin that shares structural homology with the glucagon-like peptide-1 family of insulin secretagogic hormones.
Holz GG; Habener JF
Comp Biochem Physiol B Biochem Mol Biol; 1998 Oct; 121(2):177-84. PubMed ID: 9972293
[TBL] [Abstract][Full Text] [Related]
12. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.
Parkes DG; Mace KF; Trautmann ME
Expert Opin Drug Discov; 2013 Feb; 8(2):219-44. PubMed ID: 23231438
[TBL] [Abstract][Full Text] [Related]
13. Actions of Gila monster venom on dispersed acini from guinea pig pancreas.
Raufman JP; Jensen RT; Sutliff VE; Pisano JJ; Gardner JD
Am J Physiol; 1982 May; 242(5):G470-4. PubMed ID: 6177252
[TBL] [Abstract][Full Text] [Related]
14. Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant.
Yap MKK; Misuan N
Basic Clin Pharmacol Toxicol; 2019 May; 124(5):513-527. PubMed ID: 30417596
[TBL] [Abstract][Full Text] [Related]
15. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
Greig NH; Holloway HW; De Ore KA; Jani D; Wang Y; Zhou J; Garant MJ; Egan JM
Diabetologia; 1999 Jan; 42(1):45-50. PubMed ID: 10027577
[TBL] [Abstract][Full Text] [Related]
16. Exenatide and weight loss.
Bradley DP; Kulstad R; Schoeller DA
Nutrition; 2010 Mar; 26(3):243-9. PubMed ID: 20152707
[TBL] [Abstract][Full Text] [Related]
17. Induction of insulin receptor substrate-2 expression by Fc fusion to exendin-4 overexpressed in E. coli: a potential long-acting glucagon-like peptide-1 mimetic.
Kim JW; Kim K; Ahn Y; Jeong H; Jeong H; Ryu S; Lee S; Lee C; Chung HS; Jang SH
BMB Rep; 2010 Feb; 43(2):146-9. PubMed ID: 20193135
[TBL] [Abstract][Full Text] [Related]
18. Expression and purification of exendin-4, a GLP-1 receptor agonist, in Escherichia coli.
Yin X; Wei D; Yi L; Tao X; Ma Y
Protein Expr Purif; 2005 Jun; 41(2):259-65. PubMed ID: 15866711
[TBL] [Abstract][Full Text] [Related]
19. Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2.
Schepp W; Schmidtler J; Riedel T; Dehne K; Schusdziarra V; Holst JJ; Eng J; Raufman JP; Classen M
Eur J Pharmacol; 1994 Oct; 269(2):183-91. PubMed ID: 7851494
[TBL] [Abstract][Full Text] [Related]
20. Interaction of Gila monster venom with VIP receptors in intestinal epithelium of human. A comparison with rat.
Amiranoff B; Vauclin-Jacques N; Boige N; Rouyer-Fessard C; Laburthe M
FEBS Lett; 1983 Dec; 164(2):299-302. PubMed ID: 6317454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
